Advertisement

Hormone Losses by Charcoal Hemoperfusion

  • O. Bartels
  • M. Neidhardt
  • H. Schellberger

Abstract

Clinical manifestations of hepatic coma in patients with either fulminant hepatic failure or cirrhosis result from an accumulation of toxic substances and from lack of substances which are necessary for cerebral function (Williams 1972). It seemed obvious that detoxification by charcoal hemoperfusion may aggravate deficiency of physiological substances, e.g., hormones responsible for augmented endocrine changes in hepatic coma (Bartels et al. 1977). Chang has demonstrated experimentally the effective removal of substances in the middle molecular weight range including polypeptides using hemoperfusion with the ACAC microcapsule (Chang and Migchelsen 1973). Therefore, we started in vitro and in vivo studies on the development of hemoperfusion through coated charcoal for the removal of hormones within the range of 300–6000 MW.

Keywords

Thyroid Hormone Liver Failure Fulminant Hepatic Failure Hepatic Coma Artificial Liver Support 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bartels O (1978) Haemoperfusion through activated carbon adsorbents in liver failure and hepatic coma. Acta Hepatogastroenterol (Stuttg) 25:324Google Scholar
  2. Bartels O, Neidhardt B, Neidhardt M, Schellberger H, Issel W, Waldherr A, Demling L (1977) Untersuchungen und Erfahrungen mit der Kohle-Hämoperfusion bei Leberkoma. In: Demiin L, Bartels O (eds) Entgiftung mit Hämoperfusion. Bindernagel, Friedberg, pp 119-Google Scholar
  3. Chang TMS, Migchelsen M (1973) Characterization of possible toxic metabolites in uremia and hepatic coma based on the clearance spectrum for larger molecules by the ACAC microcapsule artificial kidney. Trans Am Soc Artif Intern Organs 19:314PubMedCrossRefGoogle Scholar
  4. Hollander D, Meek JC, Manning RT (1967) Determination of free thyroxin in serum of patients with cirrhosis of the liver. N Engl J Med 276:900PubMedCrossRefGoogle Scholar
  5. Inada M, Sterlin K (1967) Thyroxin turnover and transport in Laennec’s cirrhosis of the liver. J Clin Invest 46:1275PubMedCrossRefGoogle Scholar
  6. Koczorek KR, et al. (1967) Postoperative Störung des Electrolyt- und Wasserhaushaltes. Symposion KarlsruheGoogle Scholar
  7. Müller G, Spech HJ, Wellhöfer G, Wernze H, Wilkinson SP, Bernardi M (1976) Untersuchungen zum Hyperaldosteronismus bei akuter Virus-Hepatitis, Leberzirrhose und fulminantem Leberversagen. Verh Dtsch Ges Inn Med 82Google Scholar
  8. Murray-Lyon IM, Portmann B, Gazzard BG, Williams R (1975) Analysis of the causes of death in the treatment failures. In: Williams R, Murray-Lyon IM (eds) Artificial liver support. Pitman Medical, Tunbridge Wells, pp 242–249Google Scholar
  9. Petersen PE (1960) Adrenocortical steroid metabolism and adrenal cortical function in liver disease. J Clin Invest 39:320CrossRefGoogle Scholar
  10. Sherlock S (1975) Diseases of the liver and biliary system, 5th edn. Blackwell, OxfordGoogle Scholar
  11. Williams R (1972) Problems of fulminant hepatic failure. Br Med Bull 28:114PubMedGoogle Scholar
  12. Woodbury DM, Koch A (1957) Effects of aldosterone and deoxycorticosterone in tissue electrolytes. Proc Soc Exp Biol Med 94:720PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • O. Bartels
    • 1
  • M. Neidhardt
    • 1
  • H. Schellberger
    • 1
  1. 1.Medizinische UniversitätsklinikErlangenGermany

Personalised recommendations